April 1, 2021
J&J answers allegations over vaccine problems
J&J has answered allegations about its batch of vaccines that could not be used after ingredient issues.
Pharmaceuticals, Biotechnology and Life Sciences
Tag: Johnson & Johnson
October 17, 2019
NeuClone starts dosing Stelara biosimilar candidate, NeuLara, in a Phase I clinical trial
NeuClone starts dosing NeuLara ustekinumab the first patients, a Johnson and Johnson’s Stelara biosimilar candidate, in a Phase I clinical…
October 14, 2019
Janssen gets FDA’s green light for Xarelto for prevention of blood clots
The U.S. Food and Drug Administration (FDA) has approved Xarelto (rivaroxaban) for the prevention of venous thromboembolism (VTE), or blood clots, in hospitalized acutely ill medical patients at risk for thromboembolic complications who are not at high risk of bleeding, Janssen said Monday in a press release.
September 30, 2019
JJ gets FDA’s approval of Invokana to treat diabetic kidney
FDA has approved Invokana (canagliflozin) to treat diabetic kidney disease (DKD) and reduce the risk of hospitalization for heart failure in patients with type 2 diabetes (T2D) and DKD, which is the only diabetes medicine indicated to slow the progression of diabetic nephropathy (also known as DKD) and reduce the risk of hospitalization for heart failure in patients with T2D and DKD.
September 16, 2019
Janssen files for sBLA to FDA for Tremfya
The Janssen has filed for a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) seeking first-in-class approval of guselkumab brand Tremfya, for the treatment of adult patients with active psoriatic arthritis (PsA), and expects to submit a marketing application to the European Medicines Agency seeking approval of TREMFYA as a treatment for PsA before the end of the year.
April 2, 2019
Johnson & Johnson buy Auris Health for $3.4B, plus milestons payments
Johnson & Johnson has bought Auris Health, Inc. for about $3.4 billion in cash, with additional payments of up to $2.35 billion, in the aggregate, which may be payable upon reaching certain predetermined milestones, JJ said in a statement Monday.
March 16, 2018
J&J gets offer from Platinum Equity to buy LifeScan for $2.1 billion
Johnson & Johnson has received a binding offer from Platinum Equity, a private investment firm, to acquire its LifeScan business…
February 16, 2018
Canada allows combination of Janssen’s Zytiga with ADT in to treat certain prostate cancer (mHSPC)
Johnson & Johnson’s Janssen has welcomed the news from Health Canada as it got approval to use Zytiga combined with prednisone…
February 6, 2018
Idorsia six months after demerger from Actelion posts €12M net loss, announces investing in pipeline and OPEX of €336M in 2018
Idorsia Ltd has made meaningful collaboration with industry leaders in the six and a half months since the demerger from…
June 9, 2017
J&J receives final EC approval to acquire Actelion
Johnson & Johnson has announced that, with today’s receipt of approval of the proposed acquisition of Actelion from the European Commission (EC), all regulatory approvals required to complete the transaction have been received.